within Pharmacolibrary.Drugs.ATC.J;

model J02AC03
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.96,
    Cl             = 0.0001,
    adminDuration  = 600,
    adminMass      = 200 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0046,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.00065,
    Tlag           = 780,            
    Vdp             = 0.0052,
    k12             = 6.1,
    k21             = 6.1
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>J02AC03</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Voriconazole is a triazole antifungal medication approved for the treatment of invasive aspergillosis and serious infections caused by other yeasts and fungi, such as Candida species. It is used in immunocompromised patients, including those with hematopoietic stem cell transplants or advanced HIV infection, and remains widely approved and in clinical use today.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics reported in healthy adult volunteers, both male and female, after a single oral dose under fasting conditions.</p><h4>References</h4><ol><li><p>Theuretzbacher, U, et al., &amp; Derendorf, H (2006). Pharmacokinetic/pharmacodynamic profile of voriconazole. <i>Clinical pharmacokinetics</i> 45(7) 649–663. DOI:<a href=\"https://doi.org/10.2165/00003088-200645070-00002\">10.2165/00003088-200645070-00002</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/16802848/\">https://pubmed.ncbi.nlm.nih.gov/16802848</a></p></li><li><p>Vishkautsan, P, et al., &amp; Sykes, JE (2016). Pharmacokinetics of voriconazole after intravenous and oral administration to healthy cats. <i>American journal of veterinary research</i> 77(9) 931–939. DOI:<a href=\"https://doi.org/10.2460/ajvr.77.9.931\">10.2460/ajvr.77.9.931</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/27580104/\">https://pubmed.ncbi.nlm.nih.gov/27580104</a></p></li><li><p>Mori, M, et al., &amp; Liu, P (2015). Pharmacokinetics and safety of voriconazole intravenous-to-oral switch regimens in immunocompromised Japanese pediatric patients. <i>Antimicrobial agents and chemotherapy</i> 59(2) 1004–1013. DOI:<a href=\"https://doi.org/10.1128/AAC.04093-14\">10.1128/AAC.04093-14</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/25451051/\">https://pubmed.ncbi.nlm.nih.gov/25451051</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end J02AC03;
